Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer
- Conditions
- Incurable Colorectal CancerRAS-wild-type
- Interventions
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Tianshu Liu
- Target Recruit Count
- 54
- Registration Number
- NCT02071069
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
- Conditions
- Anal Intraepithelial NeoplasiaHIV InfectionHigh-grade Squamous Intraepithelial Lesion
- Interventions
- Drug: fluorouracilDrug: imiquimodOther: questionnaire administrationOther: laboratory biomarker analysis
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 91
- Registration Number
- NCT02059499
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Laser Surgery Care, New York, New York, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Lithuanian University of Health Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT02047201
- Locations
- 🇱🇹
Lithuanian University of Health Sciences, Kaunas, Lithuania
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
- Conditions
- Stage I Pancreatic CancerStage IIB Pancreatic CancerAcinar Cell Adenocarcinoma of the PancreasStage IIA Pancreatic CancerDuct Cell Adenocarcinoma of the Pancreas
- Interventions
- Drug: oxaliplatinDrug: leucovorin calciumDrug: irinotecan hydrochlorideDrug: fluorouracilProcedure: therapeutic conventional surgeryOther: laboratory biomarker analysis
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Yale University
- Target Recruit Count
- 46
- Registration Number
- NCT02047474
- Locations
- 🇺🇸
Smilow Cancer Hospital at St. Francis Hospital, Hartford, Connecticut, United States
🇺🇸Smilow Cancer Hospital at North Haven, North Haven, Connecticut, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer
- Conditions
- Adenocarcinoma of the RectumAdenocarcinoma of the Colon
- Interventions
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Weill Medical College of Cornell University
- Registration Number
- NCT02046538
- Locations
- 🇺🇸
Weill Cornell Medical College, New York city, New York, United States
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
- Conditions
- Recurrent Rectal CancerStage IVA Rectal CancerStage IVA Colon CancerStage IVB Rectal CancerStage IVB Colon CancerRecurrent Colon Cancer
- Interventions
- Drug: MEK inhibitor MEK162Drug: leucovorin calciumDrug: fluorouracilDrug: oxaliplatinOther: pharmacological studyOther: Laboratory Biomarker Analysis
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT02041481
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
- Conditions
- BCLC Stage D Adult Hepatocellular CarcinomaRecurrent Extrahepatic Bile Duct CarcinomaLocalized Non-Resectable Adult Liver CarcinomaStage III Childhood Hepatocellular CarcinomaStage IVA Gallbladder CancerAdult CholangiocarcinomaAdvanced Adult Hepatocellular CarcinomaStage IV Childhood Hepatocellular CarcinomaRecurrent Adult Liver CarcinomaStage IIIA Gallbladder Cancer
- Interventions
- Drug: CapecitabineDrug: TrametinibDrug: FluorouracilOther: Laboratory Biomarker AnalysisDrug: Leucovorin Calcium
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT02042443
- Locations
- 🇺🇸
Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States
🇺🇸Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
- Conditions
- Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionStage IIIC Esophageal CancerAdenocarcinoma of the Gastric CardiaStage IIIA Esophageal CancerStage IIIB Esophageal Cancer
- Interventions
- Drug: oxaliplatinDrug: leucovorin calciumDrug: fluorouracilProcedure: therapeutic conventional surgeryRadiation: radiation therapyDrug: carboplatinDrug: paclitaxel
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT02037048
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
- Conditions
- Advanced Gastrointestinal Cancer
- Interventions
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 495
- Registration Number
- NCT02024607
- Locations
- 🇺🇸
Parkview Research Center, Fort Wayne, Indiana, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
- Conditions
- Pancreas Cancer
- Interventions
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 13
- Registration Number
- NCT02021422
- Locations
- 🇺🇸
Baylor Sammons Cancer Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.